Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis
Darius Armstrong‐James, Jonathan Youngs, Tihana Bicanic, Alireza Abdolrasouli, David W. Denning, Elizabeth M. Johnson, Varun Mehra, Tony Pagliuca, Brijesh Patel, Johanna Rhodes, Silke Schelenz, Anand Shah, Frank L. van de Veerdonk, Paul E. Verweij, P. Lewis White, Matthew C. Fisher
Abstract
<b>Cases of COVID-19 associated pulmonary aspergillosis (CAPA) are being increasingly reported and physicians treating patients with COVID-19-related lung disease need to actively consider these fungal co-infections</b>https://bit.ly/3feuGsQ
Topics & Concepts
Pulmonary aspergillosisMedicineCoronavirus disease 2019 (COVID-19)AspergillosisSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Lung disease2019-20 coronavirus outbreakLungPulmonary diseaseIntensive care medicineDiseaseImmunologyInfectious disease (medical specialty)VirologyInternal medicineOutbreakAntifungal resistance and susceptibility